Cargando…

A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials

BACKGROUND: The population-level summary measure is a key component of the estimand for clinical trials with time-to-event outcomes. This is particularly the case for non-inferiority trials, because different summary measures imply different null hypotheses. Most trials are designed using the hazard...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quartagno, Matteo, Morris, Tim P, Gilbert, Duncan C, Langley, Ruth E, Nankivell, Matthew G, Parmar, Mahesh KB, White, Ian R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7615295/ https://www.ncbi.nlm.nih.gov/pubmed/37337728 http://dx.doi.org/10.1177/17407745231181907

Ejemplares similares

Rethinking non-inferiority: a practical trial design for optimising treatment duration
por: Quartagno, Matteo, et al.
Publicado: (2018)

The DURATIONS randomised trial design: Estimation targets, analysis methods and operating characteristics
por: Quartagno, Matteo, et al.
Publicado: (2020)

Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation
por: Quartagno, Matteo, et al.
Publicado: (2020)

Releasing interim results from a randomised clinical trial: an example from the QUARTZ trial
por: Nankivell, Matthew, et al.
Publicado: (2011)

Why restricted mean survival time methods are especially useful for non-inferiority trials
por: Quartagno, Matteo, et al.
Publicado: (2021)

The value of evidence synthesis in randomised controlled trial (RCT) design, conduct and analysis: MRC clinical trials unit (CTU) at UCL experience
por: Tierney, Jayne F, et al.
Publicado: (2015)

The Smooth Away From Expected (SAFE) non-inferiority frontier: theory and implementation with an application to the D3 trial
por: Quartagno, Matteo, et al.
Publicado: (2023)

Choosing and changing the analysis scale in non-inferiority trials with a binary outcome
por: Li, Zhong, et al.
Publicado: (2021)

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
por: Royston, Patrick, et al.
Publicado: (2013)

A framework for the design and analysis of phase III randomised trials in uncommon diseases
por: Parmar, Mahesh, et al.
Publicado: (2015)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
por: Seymour, Matthew T, et al.
Publicado: (2011)

How do you design randomised trials for smaller populations? A framework
por: Parmar, Mahesh K. B., et al.
Publicado: (2016)

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
por: Mulvenna, Paula, et al.
Publicado: (2016)

Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit
por: Royston, Patrick, et al.
Publicado: (2011)

Survival analysis: coping with non proportional hazards in randomized trials
por: Royston, Patrick, et al.
Publicado: (2011)

An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect
por: Royston, Patrick, et al.
Publicado: (2014)

Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
por: Choodari-Oskooei, Babak, et al.
Publicado: (2013)

Adding new experimental arms to randomised clinical trials: Impact on error rates
por: Choodari-Oskooei, Babak, et al.
Publicado: (2020)

REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers
por: Merrick, Sophie, et al.
Publicado: (2023)

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated
por: Royston, Patrick, et al.
Publicado: (2016)

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
por: Muers, Martin F, et al.
Publicado: (2008)

Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial
por: Navani, Neal, et al.
Publicado: (2015)

Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer
por: Parpia, Sameer, et al.
Publicado: (2014)

A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis
por: Bratton, Daniel J, et al.
Publicado: (2013)

Discrimination-based sample size calculations for multivariable prognostic models for time-to-event data
por: Jinks, Rachel C., et al.
Publicado: (2015)

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
por: Dearnaley, David P, et al.
Publicado: (2009)

Accessing routinely collected health data to improve clinical trials: recent experience of access
por: Macnair, Archie, et al.
Publicado: (2021)

Choosing sensitivity analyses for randomised trials: principles
por: Morris, Tim P, et al.
Publicado: (2014)

Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals
por: Rehal, Sunita, et al.
Publicado: (2016)

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)
por: Langley, Ruth E, et al.
Publicado: (2013)

The use of randomisation-based efficacy estimators in non-inferiority trials
por: Gillespie, David, et al.
Publicado: (2015)

The use of randomisation-based efficacy estimators in non-inferiority trials
por: Gillespie, David, et al.
Publicado: (2017)

Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
por: Choodari-Oskooei, Babak, et al.
Publicado: (2013)

Combined test versus logrank/Cox test in 50 randomised trials
por: Royston, Patrick, et al.
Publicado: (2019)

Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial
por: Sydes, Matthew R, et al.
Publicado: (2011)

Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer
por: Zeissler, Marie-Louise, et al.
Publicado: (2020)

Sharing data from clinical trials: the rationale for a controlled access approach
por: Sydes, Matthew R, et al.
Publicado: (2015)

Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial
por: Choodari-Oskooei, Babak, et al.
Publicado: (2023)

Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial
por: Pyle, Melissa, et al.
Publicado: (2016)

Estimands in published protocols of randomised trials: urgent improvement needed
por: Kahan, Brennan C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bu32uqlrbk3fdadvdntb3p7qof